When overexpressed, PSME2 is capable of suppressing the tumorigenic activity of both the TE-1 esophageal squamous cell carcinoma cell line as well as the MKN45 gastric adenocarcinoma (GA) cell line, consistent with its potential relevance as a therapeutic target in a range of cancers 5-7. Here, PSME2 is linked to gastric adenocarcinoma.